Pfizer (PFE) was Reiterated by UBS to “Buy” according to the research note released today. The brokerage firm has raised the Price Target to $ 38 from a previous price target of $36 . UBS advised their investors in a research report released on May 4, 2016.
Many Wall Street Analysts have commented on Pfizer. Goldman Resumed Pfizer on Apr 18, 2016 to “Neutral”, Price Target of the shares are set at $35.JP Morgan Resumed Pfizer on Apr 7, 2016 to “Overweight”, Price Target of the shares are set at $38.Morgan Stanley Resumed Pfizer on Apr 7, 2016 to “Equal-Weight”, Price Target of the shares are set at $35.
On the company’s financial health, Pfizer reported $0.67 EPS for the quarter, beating the analyst consensus estimate by $ 0.12 according to the earnings call on May 3, 2016. Analyst had a consensus of $0.55. The company had revenue of $13005.00 million for the quarter, compared to analysts expectations of $12008.32 million. The company’s revenue was up 19.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.51 EPS.
Pfizer opened for trading at $32.56 and hit $33 on the upside on Monday, eventually ending the session at $32.8, with a gain of 0.28% or 0.09 points. The heightened volatility saw the trading volume jump to 3,80,66,813 shares. Company has a market cap of $202,840 M.
In a different news, on Aug 3, 2015, Loretta V Cangialosi (Sr. Vice President, Controller) sold 24,704 shares at $35.65 per share price. According to the SEC, on Jun 12, 2015, Laurie J Olson (Executive Vice President) sold 26,000 shares at $34.38 per share price. On Jun 2, 2015, Charles H Hill (Executive Vice President) sold 42,870 shares at $34.92 per share price, according to the Form-4 filing with the securities and exchange commission.
Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.